FDA Says the GLP‑1 Shortage Is Over. So Why Are ‘Semaglutide’ Shots Still Everywhere—and What’s Actually in the Vial?
The FDA ended the national shortage listing for Ozempic and Wegovy—but the vial-and-syringe semaglutide market didn’t disappear. It adapted, and regulators are signaling they’re done indulging the workaround.
Key Points
- 1Track the timeline: FDA ended Ozempic/Wegovy shortage Feb. 21, 2025—then enforcement discretion tapered through April–May 2025.
- 2Recognize the shift: by February 2026, FDA warned of “decisive steps” on GLP‑1 APIs, plus seizures and injunctions for mass-marketed copies.
- 3Verify what you’re getting: Ozempic/Wegovy are branded pens; vial-and-syringe “semaglutide” may be compounded, with dosing and quality risks.
On paper, the semaglutide shortage ended more than a year ago. In real life, the “semaglutide” market still feels like a street bazaar—vials and syringes advertised by telehealth clinics, med-spas, and online sellers, often at prices that undercut branded pens and with language that blurs the line between prescription medicine and consumer product.
The dissonance is not a mystery. On Feb. 21, 2025, the Food and Drug Administration determined the shortage of “semaglutide injection products”—the FDA-approved brands Ozempic and Wegovy—was resolved, after being listed as in shortage beginning March 2022 (Wegovy) and August 2022 (Ozempic). That is one of the most consequential regulatory sentences of the GLP‑1 era, because shortage status functioned as a kind of legal on‑ramp for compounding “copies” when the branded drugs could not meet demand.
Yet the market didn’t vanish when the FDA took semaglutide off its shortage list. It evolved.
“The FDA’s ‘shortage is over’ call was about products on a list—not a guarantee that every patient can fill every dose at every pharmacy, every time.”
— — TheMurrow Editorial
What follows is the story behind the ongoing flood of “semaglutide” offers—and why, in 2026, regulators are signaling they’re done tolerating a mass-market workaround.
What the FDA actually declared on Feb. 21, 2025—and what it didn’t
That matters because it frames the decision as an administrative, data-driven judgment: “Is the national supply picture stable enough that the shortage listing is no longer justified?” It is not a promise that distribution will be smooth or that every dosing strength will appear on every shelf.
The nuance is easy to miss because patients experience semaglutide as a series of local problems. One pharmacy has stock; another doesn’t. One dose is available; the titration step you need isn’t. One insurer covers one brand and not the other. None of those frustrations are directly answered by whether a drug is on an FDA shortage list.
Key dates that shaped the market
- March 2022: Wegovy is listed as in shortage.
- August 2022: Ozempic is listed as in shortage.
- Feb. 21, 2025: FDA declares the shortage of semaglutide injection products resolved.
- April–May 2025: FDA’s time-limited enforcement discretion windows for compounders begin to close.
That last point is where the story becomes less about supply chains and more about incentives.
The “grace period” that kept compounded semaglutide flowing into spring 2025
The answer was a carefully bounded wind-down. The FDA said it did not intend to take action against certain compounding-related violations for a limited period after Feb. 21, 2025, creating two distinct lanes:
- 503A (state-licensed pharmacies and physicians): enforcement discretion through April 22, 2025 (or later if a court decision occurred later).
- 503B (outsourcing facilities): enforcement discretion through May 22, 2025 (or later if a court decision occurred later).
Those dates are not trivia. They shaped behavior across the ecosystem—patients seeking continuity, clinics managing subscriptions, and businesses trying to bank revenue while the legal window still looked ajar.
A predictable “last call” dynamic followed. Patients and prescribers had strong incentives to lock in supplies, and providers had incentives to reassure customers that nothing would change. Even if a clinic wasn’t technically “stockpiling,” the market’s posture often resembled a continuity-of-care sprint: get refills, keep schedules, avoid interruptions.
“A time-limited enforcement window doesn’t just manage risk—it creates a deadline, and deadlines change behavior.”
— — TheMurrow Editorial
Practical implication for readers
Litigation didn’t erase the market—it clarified the stakes
Legally, that ruling reinforced the FDA’s position. Commercially, it did something subtler: it signaled that the old justification—“We’re compounding because the drug is unavailable”—was on borrowed time.
Yet consumer behavior is sticky, especially when it has been trained by months or years of scarcity and price shock. By the time the litigation worked through the courts, the GLP‑1 marketplace had already developed mature customer pipelines:
- Med-spas offering “weight loss shots” as a lifestyle service.
- Telehealth prescribers optimizing convenience: online intake, quick shipping, recurring billing.
- Weight loss clinics packaging medication with coaching and check-ins.
A court decision does not undo those infrastructures overnight. It also does not erase the underlying demand that fueled them.
Multiple perspectives: patient access vs. regulatory guardrails
Those positions can coexist in the same person: a patient can appreciate the convenience of a compounded product while also wanting regulators to prevent low-quality, mass-marketed imitations.
The 2026 shift: from “shortage policy” to a tougher enforcement posture
That language is not subtle. It also reflects a strategic pivot: if the shortage pathway once functioned as a permissive channel for compounding, the agency is now emphasizing control points that don’t depend on shortage status—particularly API sourcing and marketing claims.
The practical meaning is straightforward. After the shortage determination and the expiration of enforcement discretion, businesses that continued to mass-market compounded GLP‑1 products faced a new risk profile. Even if a company argued patients still struggled to find the branded pens in certain locations, the legal “permission slip” of national shortage was gone.
Reporting in February 2026 around Hims & Hers illustrated how long the compounded GLP‑1 business persisted after the shortage—and how quickly regulatory pressure and legal threats can reshape corporate plans.
“Once the shortage rationale disappears, the next fight is over APIs and advertising—the supply chain and the sales pitch.”
— — TheMurrow Editorial
What enforcement looks like in the real world
What’s actually in the vial when the label says “semaglutide”?
FDA-approved semaglutide: Ozempic and Wegovy
For readers, that’s the reference point: known formulation, regulated manufacturing, and a formal FDA approval framework for safety, quality, and effectiveness.
Compounded semaglutide: narrower legitimacy, broader marketing
The FDA has also warned about dosing errors associated with compounded products. The agency’s position is consistent: compounded drugs do not receive FDA premarket review, and risk can rise when products are widely distributed, repackaged, or promoted with simplified, consumer-style messaging.
Key Insight
The uncomfortable truth: sameness is hard to verify from a website
Why semaglutide offers still feel ubiquitous—even after the shortage ended
1) Demand didn’t fall just because supply improved
2) The ecosystem built during scarcity didn’t disappear
3) Enforcement is real—but uneven enough to sustain gray-market behavior
Readers should understand that uneven enforcement is not the same as permission.
A real-world case study: the spring 2025 “continuity rush”
A patient began compounded semaglutide after months of being unable to consistently access branded pens. When the FDA declared the shortage resolved on Feb. 21, 2025, the patient’s provider reassured them: treatment would continue, no interruptions, business as usual.
That reassurance aligned with the FDA’s time-limited enforcement discretion: 503A through April 22, 2025 and 503B through May 22, 2025. Clinics had a window to keep dispensing without immediate fear of action tied to the shortage status change.
As the spring progressed, the patient saw new signals: shifting clinic policies, new consent forms, subtle changes in how products were described, and sometimes changes in sourcing or pricing. Then came the legal and regulatory tightening—culminating in the June 2025 court decision upholding FDA’s removal and, later, the more aggressive February 2026 FDA messaging about restricting GLP‑1 APIs used in mass-marketed, non-approved compounded products.
The continuity rush explains why many patients still report compounded supplies long after February 2025. The later crackdown messaging explains why that continuity may feel less stable in 2026.
What readers should do now: a practical checklist for safer decisions
Here are practical steps grounded in the FDA’s stated concerns about oversight, copycat compounding, and dosing risk:
Safer-decision checklist
- ✓- Ask what product you’re receiving. Is it an FDA-approved pen (Ozempic/Wegovy), or a compounded product?
- ✓- Ask why compounding is needed. The FDA’s general position is that compounded drugs should be used when patient needs cannot be met by an available FDA-approved drug.
- ✓- Clarify dosing and administration. The FDA has flagged dosing errors associated with compounded products; make sure instructions are explicit and personalized.
- ✓- Be wary of mass-market substitution language. The FDA’s 2026 messaging targets non-approved GLP‑1 drugs mass-marketed as alternatives.
- ✓- Expect policy changes. The end of the shortage designation (Feb. 21, 2025) and the end of the enforcement discretion windows (April/May 2025) mean the ground can shift quickly.
The highest-functioning healthcare decisions are boring: clear documentation, verifiable sourcing, and a prescriber who treats medication as medicine—not content for a sales funnel.
The larger meaning of “shortage over”: a warning about how quickly medicine becomes consumer commerce
The FDA’s Feb. 21, 2025 shortage resolution was a pivot point. So were the April 22, 2025 and May 22, 2025 wind-down dates. So was the June 2025 court decision. And so is the FDA’s February 2026 posture signaling “decisive steps” on GLP‑1 APIs.
Patients deserve empathy for navigating a confusing system. They also deserve candor: when medicine is sold like a commodity, quality and accountability can become optional unless regulators—and consumers—insist otherwise.
The market is still full of “semaglutide” because the story was never only about a shortage. It was about demand, money, and the fragile boundary between individualized care and industrial-scale imitation.
Frequently Asked Questions
Did the FDA really say the semaglutide shortage is over?
Yes. On Feb. 21, 2025, the FDA determined the shortage of “semaglutide injection products”—specifically Ozempic and Wegovy—was resolved. The agency based its decision on supply-and-demand analysis that relied heavily on manufacturer submissions from Novo Nordisk, alongside other sources including telehealth companies and compounders.
If the shortage is over, why do pharmacies and patients still report access problems?
The FDA’s determination applies to the national shortage listing, not to every local availability issue. Patients can still encounter uneven distribution, dose-specific gaps, insurance hurdles, and pharmacy-level variability. “Not on the shortage list” doesn’t guarantee that any given patient can fill a prescription immediately in their ZIP code.
Is compounded semaglutide still legal?
Compounding can be legal in narrow circumstances, but the FDA has made clear that compounded drugs don’t undergo FDA premarket review and should generally be used when patient needs cannot be met by an available FDA-approved drug. After the shortage resolution, compounding products that are “essentially a copy” becomes far more legally constrained.
What were the FDA’s grace periods after Feb. 21, 2025?
The FDA said it did not intend to take action against certain violations for a limited time: for 503A compounders through April 22, 2025, and for 503B outsourcing facilities through May 22, 2025 (with potential timing adjustments tied to court decisions). Those windows helped explain why compounded supplies continued into spring 2025.
What changed in 2026?
In February 2026, the FDA announced it intends to take “decisive steps to restrict GLP‑1 active pharmaceutical ingredients (APIs)” used in non-FDA-approved compounded products that are mass-marketed as alternatives to approved drugs. The agency also warned of enforcement actions such as seizure and injunction, signaling a tougher posture beyond shortage-related policies.
What’s the safest way to know you’re getting FDA-approved semaglutide?
Ozempic and Wegovy are FDA-approved semaglutide injections delivered as branded pen products. If you’re receiving a vial and syringe marketed as “semaglutide,” that may indicate a compounded product rather than an FDA-approved pen. Patients should ask directly which product they are being prescribed and dispensed, and why.
